HOME >> MEDICINE >> NEWS
Randomisation phase of the DIRECT programme (DIabetic REtinopathy Candesartan Trials) completed

The randomisation of patients into the landmark DIabetic REtinopathy Candesartan Trials (DIRECT) was completed in February. A total of 5238 patients in around 300 investigational sites in 30 EU countries have now been randomised into the 3 trial/studies that comprise the DIRECT Programme. The DIRECT Programme is the first Programme designed to establish whether treatment with an angiotensin II type 1 (AT1) receptor blocker, candesartan cilexetil, targeting the renin angiotensin system (RAS), can provide effective treatment against the onset and progression of diabetic retinopathy. In this double-blind programme, patients are assigned to receive 32 mg of candesartan cilexetil or placebo.

The DIRECT programme, launched on Nov. 1, 2000, is being coordinated through EURODIAB, a European diabetes research network, based at University College, London, and Imperial College, London, and overseen by an independent Steering Committee, chaired by Professor Anne-Katrin Sjolie, University of Southern Denmark, Odense. The Steering Committee consists of leading ophthalmologists, diabetologists and epidemiologists, and has scientific responsibility for the DIRECT programme.

"We are very pleased to have completed this initial phase of the DIRECT Programme, with more patients than originally planned. DIRECT represents an important step forward in the fight against visual loss caused by diabetic retinopathy", said Professor Sjolie. "This important Programme will tell us more about the potential for using a drug such as candesartan to halt progression of, and possibly prevent, diabetic retinopathy, a common and frightening condition among people with diabetes. We look forward to the results from the DIRECT Programme, which will hopefully identify candesartan as a new addition to current treatment and help to limit retinal damage and, in some patients, preserve vision."

Retinopathy can ultimately lead to blindness in both type 1 and type 2 diabetic patients. I
'"/>

Contact: Takashi Kikuchi
Kikuchi_Takashi@takeda.co.jp
81-66-204-2258
Japan Corporate News Network
2-Mar-2004


Page: 1 2 3

Related medicine news :

1. US FDA grants full approval to DOXIL(R) following submission of phase III data
2. Less risks for patients participating in early phase cancer drug trials
3. Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection
4. Exemestane beats tamoxifen in first phase III head to head trial in advanced breast cancer
5. New vaccine for herpes in final trial phase
6. Antiepileptic drug developed at Hebrew University to undergo phase three clinical trials
7. Exanta - pivitol data from largest ever phase III stroke prevention trial announced at ACC
8. Results of NUVANCE phase I/II asthma trial presented
9. Circulation publishes phase I study of ENBREL in patients with chronic heart failure
10. Influenza vaccination programmes for children in USA and Canada based on little evidence
11. New programme will train the next generation of health leaders

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/11/2020)... ... August 11, 2020 , ... 2020 has seen a drastic change in how things ... CDC recommended that everyone wears a face mask in public. Now, most states have made ... , Earlier this year, all medical professionals in the U.S.A realized the shortage of ...
(Date:8/9/2020)... ... August 10, 2020 , ... Dr. Angela Abraham has been appointed as ... Dr. Abraham will be leading the drive to foster a more equitable and bias-free ... 13% Promise, a new initiative led by Black Eyecare Perspective and dedicated to increasing ...
(Date:8/7/2020)... ... August 07, 2020 , ... ... Alexandria, Virginia. Led by Dr. Mojgan Mazhari, this well-respected practice offers advanced smile ... & Smile Studio is among an exclusive group of dental practices with a ...
(Date:8/5/2020)... ... August 05, 2020 , ... ... Learning (SEL) program, has been named to the inaugural list of Best Digital ... , This recognition honors electronic resources that provide enhanced learning and curriculum ...
(Date:8/5/2020)... ... August 05, 2020 , ... In its ... to unprecedented challenges. Regardless of the obstacle - shortages of tests, ventilators and ... and the cancellation or postponement of all nonessential services - providers across the ...
Breaking Medicine News(10 mins):
(Date:8/3/2020)... ... ... Hide-a-Mask, a hat with a hidden face mask built-in, has tripled its goal ... Hide-a-Mask is ideal for anyone who is forgetful or reluctant to wear a mask. ... a mask at your fingertips is a great way to navigate stores, airports and ...
(Date:7/31/2020)... Ariz. (PRWEB) , ... July 31, 2020 , ... ... received FDA clearance for reprocessing the St. Jude Medical BRK Transseptal Needle and ... transseptal needles is a milestone in single-use device reprocessing, as no other company ...
(Date:7/31/2020)... (PRWEB) , ... July 31, 2020 , ... ... in partnership with Netquest, a global panel and data collection provider, recently released ... 1502 adults, across the United Kingdom, Germany and France. , “COVID-19 continues to ...
Breaking Medicine Technology:
Cached News: